The “GSK3 hypothesis in AD” suggests that the overactivation of GSK-3β is closely related to several features of the pathology of AD, including microglia-mediated inflammation, Aβ production, APP processing, tau phosphorylation, neuronal death, and cognitive deficits [52]. This evidence concerns the gene MAPT and Alzheimer disease.